单次玻璃体腔注射雷珠单抗联合激光治疗视网膜分支静脉阻塞继发黄斑水肿

doi:10.3760/cma.j.issn.1674-845X.2018.03.008

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (646 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective: To assess the efficacy of single intravitreal injection of ranibizumab with laser photocoagulation for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). Methods: In this retrospective study, 52 patients (52 eyes) during June 2014 to December 2016 at Taizhou Municipal Hospital with macular edema secondary to BRVO were diagnosed by fundus fluorescence angiography. The patients were divided into two groups, one receiving laser photocoagulation alone and the other receiving a single intravitreal injection of ranibizumab. The injection group was further divided into two groups,one receiving the injection before laser therapy and one receiving afterwards. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded before the therapy and at one and six
months afterwards. Repeated measurement analysis of variance, one-way analysis of variance, and paired t-tests were used to analyze the data. Results: Before the therapy, and at one and six months after therapy,the total difference of BCVA among the three groups was statistically significant (F=18.28, P=0.011).Objective: To assess the efficacy of single intravitreal injection of ranibizumab with laser photocoagulation for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). Methods: In this retrospective study, 52 patients (52 eyes) during June 2014 to December 2016 at Taizhou Municipal Hospital with macular edema secondary to BRVO were diagnosed by fundus fluorescence angiography. The patients were divided into two groups, one receiving laser photocoagulation alone and the other receiving a single intravitreal injection of ranibizumab. The injection group was further divided into two groups,one receiving the injection before laser therapy and one receiving afterwards. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded before the therapy and at one and six months afterwards. Repeated measurement analysis of variance, one-way analysis of variance, and paired t-tests were used to analyze the data. Results: Before the therapy, and at one and six months after therapy,the total difference of BCVA among the three groups was statistically significant (F=18.28, P=0.011).

Key words： retinal vein occlusion macular edema ranibizumab laser photocoagulation

Received: 03 July 2017

Corresponding Authors: Haijian Wu, Department of Ophthalmology, Taizhou Municipal Hospital, Taizhou 318000, China (Email: tzwhj@126.com)

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhiwei Xu
	Haijian Wu
	Lingyan Jin
	Guangen Yan

Cite this article:

Zhiwei Xu,Haijian Wu,Lingyan Jin等. Single Intravitreal Injection of Ranibizumab with Laser Photocoagulation for Macular Edema Following Branch Retinal Vein Occlusion[J]. Chinese Journal of Optometry Ophthalmology and Visual science, 2018, 20(3): 168-173.

URL:

https://www.cjoovs.com/EN/10.3760/cma.j.issn.1674-845X.2018.03.008 OR https://www.cjoovs.com/EN/Y2018/V20/I3/168

[1]	Klein R, Moss SE, Meuer SM, et al. The 15-year cumulative incidence of retinal vein occlusion: The Beaver Dam Eye Study. Arch Ophthalmol, 2008, 126(4): 513-518. DOI: 10.1001/
	archopht.126.4.513.
[2]	Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review.Ophthalmology, 2010, 117(6): 1094-1101. DOI: 10.1016/
	archopht.126.4.513.
[2]	Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review.Ophthalmology, 2010, 117(6): 1094-1101. DOI: 10.1016/
	j.ophtha.2010.01.058.
	j.ophtha.2010.01.058.
[3]	Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol, 1984, 98(3): 271-282.
[4]	陆秉文, 吴星伟. 视网膜静脉阻塞继发黄斑水肿的治疗进展.中华眼底病杂志, 2013, 29(6): 640-644. DOI: 10.3760/cma.j.issn.1005-1015.2013.06.028.
[5]	林莉, 陈松. 玻璃体腔注射抗血管内皮生长因子单克隆抗体ranibizumab治疗视网膜静脉阻塞黄斑水肿的研究现状.中华眼底病杂志, 2013, 29(6): 637-640. DOI: 10.3760/cma.j.issn.1005-1015.2013.06.029.
[6]	陈中山, 宋艳萍, 丁琴, 等. 眼底血管样条纹并发脉络膜新生血管的临床特征及联合治疗. 中华眼视光学与视觉科学杂志, 2015, 17(3): 166-170.DOI:10.3760/cma.j.issn.1674845X.2015.03.009.
[3]	Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol, 1984, 98(3): 271-282.
[4]	陆秉文, 吴星伟. 视网膜静脉阻塞继发黄斑水肿的治疗进展.中华眼底病杂志, 2013, 29(6): 640-644. DOI: 10.3760/cma.j.issn.1005-1015.2013.06.028.
[5]	林莉, 陈松. 玻璃体腔注射抗血管内皮生长因子单克隆抗体ranibizumab治疗视网膜静脉阻塞黄斑水肿的研究现状.中华眼底病杂志, 2013, 29(6): 637-640. DOI: 10.3760/cma.j.issn.1005-1015.2013.06.029.
[6]	陈中山, 宋艳萍, 丁琴, 等. 眼底血管样条纹并发脉络膜新生血管的临床特征及联合治疗. 中华眼视光学与视觉科学杂志, 2015, 17(3): 166-170.DOI:10.3760/cma.j.issn.1674845X.2015.03.009.
[7]	Pielen A, Mirshahi A, Feltgen N, et al. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized
	clinical trial. Acta Ophthalmol, 2015, 93(1): e29-37. DOI:10.1111/aos.12488.
[8]	郑红梅, 邢怡桥, 陈长征, 等. 玻璃体腔注射抗血管内皮生长因子单克隆抗体ranibizumab 联合格栅样激光光凝治疗视网膜分支静脉阻塞合并黄斑水肿疗效观察. 中华眼底病杂志, 2012, 28(5): 472-476. DOI: 10.3760/cma.j.issn.1005-1015.2012.05.010.
[9]	Regnier SA, Larsen M, Bezlyak V, et al. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network metaanalysis.BMJ Open, 2015, 5(6): e007527. DOI: 10.1136/bmjopen-2014-007527.
[7]	Pielen A, Mirshahi A, Feltgen N, et al. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized
	clinical trial. Acta Ophthalmol, 2015, 93(1): e29-37. DOI:10.1111/aos.12488.
[8]	郑红梅, 邢怡桥, 陈长征, 等. 玻璃体腔注射抗血管内皮生长因子单克隆抗体ranibizumab 联合格栅样激光光凝治疗视网膜分支静脉阻塞合并黄斑水肿疗效观察. 中华眼底病杂志, 2012, 28(5): 472-476. DOI: 10.3760/cma.j.issn.1005-1015.2012.05.010.
[9]	Regnier SA, Larsen M, Bezlyak V, et al. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network metaanalysis.BMJ Open, 2015, 5(6): e007527. DOI: 10.1136/bmjopen-2014-007527.
[10]	Tadayoni R, Waldstein SM, Boscia F, et al. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of
	BRIGHTER. Ophthalmology, 2016, 123(6): 1332-1344. DOI:10.1016/j.ophtha.2016.02.030.
[10]	Tadayoni R, Waldstein SM, Boscia F, et al. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of
	BRIGHTER. Ophthalmology, 2016, 123(6): 1332-1344. DOI:10.1016/j.ophtha.2016.02.030.
[11]	Tan MH, McAllister IL, Gillies ME, et al. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
	Am J Ophthalmol, 2014, 157(1): 237-247.e1. DOI: 10.1016/j.ajo.2013.08.013.
[11]	Tan MH, McAllister IL, Gillies ME, et al. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
	Am J Ophthalmol, 2014, 157(1): 237-247.e1. DOI: 10.1016/j.ajo.2013.08.013.
[12]	Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase Ⅲ study.
	Ophthalmology, 2010, 117(6): 1102-1112.e1. DOI: 10.1016/j.ophtha.2010.02.021.
[13]	Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase Ⅲ study.Ophthalmology, 2011, 118(8): 1594-1602. DOI: 10.1016/j.ophtha.2011.02.022.
[14]	Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology, 2014, 121(1):209-219. DOI: 10.1016/j.ophtha.2013.08.038.
[15]	Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term followup in the HORIZON trial. Ophthalmology, 2012, 119(4): 802-809. DOI: 10.1016/j.ophtha.2011.12.005.
[16]	C a m p o c h i a r o PA , H a f i z G , M i r TA , e t a l . S c a t t e r photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: The RELATE Trial. Ophthalmology, 2015, 122(7): 1426-1437. DOI: 10.1016/j.ophtha.2015.04.006.
[12]	Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase Ⅲ study.
	Ophthalmology, 2010, 117(6): 1102-1112.e1. DOI: 10.1016/j.ophtha.2010.02.021.
[13]	Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase Ⅲ study.Ophthalmology, 2011, 118(8): 1594-1602. DOI: 10.1016/j.ophtha.2011.02.022.
[14]	Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology, 2014, 121(1):209-219. DOI: 10.1016/j.ophtha.2013.08.038.
[15]	Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term followup in the HORIZON trial. Ophthalmology, 2012, 119(4): 802-809. DOI: 10.1016/j.ophtha.2011.12.005.
[16]	C a m p o c h i a r o PA , H a f i z G , M i r TA , e t a l . S c a t t e r photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: The RELATE Trial. Ophthalmology, 2015, 122(7): 1426-1437. DOI: 10.1016/j.ophtha.2015.04.006.